title: [Current strategies against multi-drug resistant organisms].
abstract: The global spread of multi-drug resistant organisms (MDRO) is a major threat to public health. Fighting MDRO spread requires a multi-faceted approach as summarized in the German Antibiotic Resistance Strategy (DART). In the hospital, this includes antibiotic stewardship concepts and strict infection control measures. Treatment of MDRO is sophisticated. Within the last years, several antibiotics with activity against MRSA were launched and facilitate an individual therapy according to site of infection and co-morbidities. In contrast, novel antibiotics against carbapenemase producing Gram-negatives are still lacking. Current studies have shown, that a colistin-based combination treatment can improve the prognosis in these patients. The following article reviews MDRO definitions, burden of disease, treatment options and general strategies against MDRO.
authors.affiliation: Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena.
authors.forename: Mathias W
authors.initials: MW
authors.lastname: Pletz
authors.affiliation: Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Klinikum Peine.
authors.forename: Christian
authors.initials: C
authors.lastname: Eckmann
authors.affiliation: Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena.
authors.forename: Stefan
authors.initials: S
authors.lastname: Hagel
authors.affiliation: Geriatrische Klinik und Tagesklinik, Lehrstuhl für Geriatrie, Universität Witten / Herdecke.
authors.forename: Hans Jürgen
authors.initials: HJ
authors.lastname: Heppner
authors.affiliation: Consultant Infektiologie, Ober-Ramstadt.
authors.forename: Kora
authors.initials: K
authors.lastname: Huber
authors.affiliation: Klinikapotheke, Klinikum Augsburg.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kämmerer
authors.affiliation: Institut für Laboratoriumsmedizin, Mikrobiologie, Hygiene, Umweltmedizin und Transfusionsmedizin, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden.
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Schmitz
authors.affiliation: Dr. Wilke GmbH - Inspiring Health, München.
authors.forename: Michael
authors.initials: M
authors.lastname: Wilke
authors.affiliation: Klinische Mikrobiologie und Krankenhaushygiene, Klinikum der Universität München.
authors.forename: Béatrice
authors.initials: B
authors.lastname: Grabein
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D003091:Colistin / Q000627:therapeutic use; D017281:Cost of Illness; D003428:Cross Infection / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D004359:Drug Therapy, Combination; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy
chemical_list: D000900:Anti-Bacterial Agents; D003091:Colistin